ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating reiterated by investment analysts at Northland Securities in a report issued on Wednesday. They presently have a GBX 181 ($2.40) target price on the stock. Northland Securities’ price target indicates a potential upside of 132.05% from the stock’s current price.

Separately, Northland Capital Partners reiterated a “buy” rating and set a GBX 181 ($2.40) price objective on shares of ImmuPharma PLC in a research report on Thursday, September 21st.

Shares of ImmuPharma PLC (LON:IMM) opened at 77.00 on Wednesday. The firm’s market capitalization is GBX 99.73 million. ImmuPharma PLC has a 52-week low of GBX 31.44 and a 52-week high of GBX 87.00. The company’s 50-day moving average is GBX 51.40 and its 200 day moving average is GBX 52.80.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/immupharma-plc-imm-stock-rating-reaffirmed-by-northland-securities.html.

About ImmuPharma PLC

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Stock Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related stocks with our FREE daily email newsletter.